Xeltis raises $22 (Netherlands, Jul 2026)
Reach the investors backing rounds like this
Backed by Horizon 3 Healthcare, European Innovation Council +4 more · verified emails and LinkedIn on Datapile
Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue - EU-Startups
Xeltis is a commercial-stage MedTech company developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. The company aims to improve patient outcomes in hemodialysis vascular access and cardiovascular replacements, addressing significant unmet needs in these areas.
Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue EU-Startups
| Sep 02, 2026 | Wonderful | $550.0M | Series C | Netherlands |
| Aug 29, 2026 | Clementine | $1.8M | Seed | Netherlands |
| Aug 04, 2026 | Ore Energy | $43.0M | Series A | Netherlands |
| Aug 01, 2026 | Keiron Printing Technologies | $22.0M | Series A | Netherlands |
7,160 investors back startups in Netherlands
You just read who funded Xeltis. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.